Table 1 Clinicopathological and demographic characteristics of the study population classified by the study phase
From: Urine cell-based DNA methylation classifier for monitoring bladder cancer
Discovery phase | Validation phase | |
|---|---|---|
Training set | Testing set | |
N bladder cancer (%) | N R-PFBC (%) | |
Gender | ||
Male | 86 (77) | 135 (78) |
Female | 25 (23) | 38 (22) |
Age | ||
Mean | 72 | 68 |
Range | 39–98 | 26–99 |
Stage and grade | ||
Tis | 7 (6) | 13 (8) |
Ta LG | 26 (23) | 61 (35) |
Ta HG | 11 (10) | 20 12) |
T1 LG | 20 (18) | 35 (20) |
T1 HG | 22 (20) | 44 (25) |
> T2 LG | 1 (1) | – |
> T2 HG | 24 (22) | – |
Subtotals | 111 | 173 |
N control (%) | ||
Gender | ||
Male | 29 (51) | – |
Female | 28 (49) | – |
Age | ||
Mean | 60 | – |
Range | 22–82 | – |
Urinary condition | ||
BPH | 11 (19) | – |
Urolithiasis | 13 (23) | – |
Incontinence | 2 (4) | – |
Benign bladder disease | 1 (2) | – |
Urinary tract infections | 12 (21) | – |
Non-urological diseases | 18 (32) | – |
Subtotals | 57 | – |
N NR-PFBC (%) | ||
Gender | ||
Male | – | 217 (76) |
Female | – | 68 (24) |
Age | ||
Mean | – | 69 |
Range | – | 26–92 |
Stage and grade previous TURBT | ||
Tis | – | 21 (7) |
Ta LG | – | 100 (35) |
Ta HG | – | 53 (19) |
T1 LG | – | 22 (8) |
T1 HG | – | 82 (29) |
T2 HG | – | 3 (1) |
Tx LG | – | 2 (1) |
Tx HG | – | 2 (1) |
Subtotals | – | 285 |
Total | 168 | 458 |